Clinical trials: Patients With Diabetes.
Diabetes Mellitus
Effect of Albiglutide, When Added to Standard Blood Glucose Lowering Therapies, on Major Cardiovascular Events in Subjects With Type 2 Diabetes Mellitus
Albiglutide is an analogue of glucagon-like peptide-1 (GLP-1), used to treat type 2 diabetes This study will test whether albiglutide affects the occurrence of major cardiovascular events such as heart attacks or strokes and…
- Trial name
- NCT02465515
- Testing
- Albiglutide 30 mg, Albiglutide 50 mg
- Where
- 607 sites in United States, Argentina and 26 more
- Volunteers
- 9,463 people
- Sponsor
- GlaxoSmithKline
Diabetic Nephropathies
Safety and Efficacy of Different Oral Doses of BAY94-8862 in Japanese Subjects With Type 2 Diabetes Mellitus and the Clinical Diagnosis of Diabetic Nephropathy (ARTS-DN Japan)
This study will be conducted in Japanese subjects with type 2 diabetes mellitus and the clinical diagnosis of Diabetic Nephropathy( DN) using a multi-center, randomized, adaptive, double-blind, placebo-controlled, parallel-group…
- Trial name
- NCT01968668
- Testing
- BAY94-8862, BAY 94-8862
- Where
- 16 sites in Japan
- Volunteers
- 96 people
- Sponsor
- Bayer
Diabetes Mellitus, Type 2
A Study of Dulaglutide (LY2189265) in Participants With Type 2 Diabetes Mellitus in India
The main purpose of this study is to evaluate safety of dulaglutide in participants with type 2 diabetes mellitus in India.
- Trial name
- NCT05659537
- Testing
- Dulaglutide
- Where
- 7 sites in India
- Volunteers
- 212 people
- Sponsor
- Eli Lilly and Company
Diabetes Mellitus Type 2
A Study of Taspoglutide Versus Exenatide for the Treatment of Patients With Type 2 Diabetes Mellitus Inadequately Controlled With Metformin, Thiazolidinedione or a Combination of Both.
This 3-arm study will assess the efficacy, safety and tolerability of taspoglutide compared with exenatide in patients with type 2 diabetes mellitus inadequately controlled with metformin, thiazolidinedione or a combination of…
- Trial name
- NCT00717457
- Testing
- exenatide, taspoglutide
- Where
- 216 sites in United States, Argentina and 24 more
- Volunteers
- 1,189 people
- Sponsor
- Hoffmann-La Roche
Diabetes, Diabetes Mellitus, Type 2
Observational Study to Observe the Safety of Levemir® Treatment in Patients With Type 2 Diabetes
This observational study is conducted in Europe. The study aims to observe the incidence of serious adverse drug reactions in subjects with type 2 diabetes during Levemir® treatment.
- Trial name
- NCT00735501
- Testing
- insulin detemir
- Where
- 2 sites in Denmark, Sweden
- Volunteers
- 314 people
- Sponsor
- Novo Nordisk A/S
Type 2 Diabetes Mellitus
Monotherapy Study of MP-513 in Patients With Type 2 Diabetes
The purpose of this study is to evaluate the efficacy and safety of MP-513 (Teneligliptin) in patients with type 2 Diabetes for 12 weeks administration.
- Trial name
- NCT00998881
- Testing
- Teneligliptin 20 mg
- Where
- Japan
- Volunteers
- 203 people
- Sponsor
- Tanabe Pharma Corporation
Diabetic Neuropathies, Diabetes Mellitus, Insulin-Dependent
Treatment for Symptomatic Peripheral Neuropathy in Patients With Diabetes
The purpose of this protocol is to determine if an investigational drug is effective in treating nerve malfunction in diabetes.
- Conditions
- Diabetic Neuropathies, Diabetes Mellitus, Insulin-Dependent, Diabetes Mellitus, Non-Insulin-Dependent
- Trial name
- NCT00044395
- Testing
- Ruboxistaurin mesylate
- Where
- 39 sites in United States, Australia and 7 more
- Volunteers
- 200 people
- Sponsor
- Eli Lilly and Company
Diabetes (Insulin-requiring, Type 1 or Type 2), Pancreatogenic Diabetes Mellitus
DIA:CONN P8(Smart Insulin Pen) Study in Diabetes Patients
A Multicenter, Open label, Randomized, Comparative Study to Evaluate the Efficacy and Safety of Electric Smart Insulin Pen DIA:CONN P8 in patients with Type 1, Type 2 or Pancreatogenic Diabetes Mellitus under Multiple Dose…
- Trial name
- NCT06406439
- Testing
- Smart Insulin Pen, Injection of bolus insulin via conventional therapy using insulin pen
- Where
- 9 sites in South Korea
- Volunteers
- 120 people
- Sponsor
- G2e Co., Ltd
Type II Diabetes Mellitus, Dyslipidemia
Study Comparing Pitavastatin and Atorvastatin in Patients With Type II Diabetes Mellitus and Combined Dyslipidemia
The purpose of this study is to compare the efficacy and safety of pitavastatin with that of atorvastatin in patients with type II diabetes mellitus (type II DM) and combined dyslipidemia.
- Trial name
- NCT00309751
- Testing
- Pitavastatin, Atorvastatin
- Where
- 35 sites in Denmark, Germany and 4 more
- Volunteers
- 418 people
- Sponsor
- Kowa Research Europe
Type 1 Diabetes
Efficacy and Safety of Diamyd® in Children and Adolescents With Type 1 Diabetes
This is a randomized, placebo-controlled phase II study to investigate if a prime and boost of 20ug Diamyd® (rhGAD65 formulated in Alhydrogel®), administered subcutaneously four weeks apart, is safe and can preserve beta cell…
- Trial name
- NCT00435981
- Testing
- rhGAD65 formulated in Alhydrogel® (Diamyd®)
- Where
- 8 sites in Sweden
- Volunteers
- 70 people
- Sponsor
- Diamyd Therapeutics AB
Type 2 Diabetes Mellitus
Comparison of Two Treatment Regimens in Patients With Type 2 Diabetes After Short-term Intensive Insulin Therapy
Primary Objective: To test the hypothesis that basal insulin based treatment (G+) is noninferior to twice-daily premixed insulin (PM-2) in term of hemoglobin A1c (glycosylated hemoglobin, HbA1c) reduction from baseline to end of…
- Trial name
- SWITCH (NCT03359837)
- Testing
- INSULIN GLARGINE (HOE901), Insulin Glulisine, Biphasic insulin aspart 30
- Where
- China
- Volunteers
- 384 people
- Sponsor
- Sanofi
Hyperlipidemia
Prospective Evaluation of Proteinuria and Renal Function in Non-diabetic Patients With Progressive Renal Disease
The purpose of this study is to evaluate the effects of Crestor (rosuvastatin) and (Lipitor) atorvastatin on urinary protein excretion over 1 year in non-diabetes with moderate proteinuria and hypercholesterolaemia.
- Trial name
- PLANET II (NCT00296400)
- Testing
- Rosuvastatin, Atorvastatin
- Where
- 107 sites in United States, Brazil and 9 more
- Volunteers
- 237 people
- Sponsor
- AstraZeneca
COVID-19 Pneumonia
Evaluation of Immunogenicity and Safety of COVID-19 Vaccine (Produced in Wuhan) in Patients With Hypertension and/or Diabetes
To evaluate the post-marketing immunogenicity and safety of the inactivated severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) vaccine (Vero cells) in patients aged 60 years or older with hypertension and/or diabetes…
- Trial name
- NCT05065892
- Testing
- COVAX
- Where
- 3 sites in China
- Volunteers
- 1,440 people, healthy volunteers welcome
- Sponsor
- China National Biotec Group Company Limited
Type 2 Diabetes Mellitus
Phase IV Study With a 36-week Extension Period to Evaluate the Efficacy and Safety of Dapagliflozin Therapy When Added to the Therapy of Japanese Patients With Type 2 Diabetes With Inadequate Glycemic Control on Insulin.
Japanese male and female patients with Type 2 Diabetes and aged ≥ 20 years old, with inadequate glycemic control on insulin defined as Haemoglobin A1c ≥ 7.2% and < 11% will be enrolled into the wash-out phase or directly into the…
- Trial name
- NCT02157298
- Testing
- Dapagliflozin 5 mg
- Where
- 14 sites in Japan
- Volunteers
- 266 people
- Sponsor
- AstraZeneca
Type 1 Diabetes Mellitus, Diabetes
Single-dose Study to Evaluate Safety, Tolerability, and Pharmacodynamics of REMD-477 in Subjects With Type 1 Diabetes Mellitus
This is a randomized, placebo-controlled, double-blind study to evaluate safety, tolerability and pharmacodynamics of REMD-477 in subjects who have Type 1 diabetes and are currently receiving insulin treatment.
- Trial name
- NCT02715193
- Testing
- REMD-477
- Where
- 2 sites in United States
- Volunteers
- 21 people
- Sponsor
- REMD Biotherapeutics, Inc.
Type 2 Diabetes Mellitus
A Placebo Controlled Safety and Efficacy Study of MSDC-0160 in Type 2 Diabetes With Active Comparator
The purpose of this study is to determine if MSDC-0160 is effective in the treatment of Type 2 diabetes.
- Trial name
- NCT00760578
- Testing
- Pioglitazone, MSDC-0160 90 mg, MSDC-0160 220 mg
- Where
- 8 sites in United States
- Volunteers
- 86 people
- Sponsor
- Metabolic Solutions Development Company
Hypercholesterolemia, Atherosclerosis
Switching to Rosuvastatin Versus Adding Ezetimibe to Atorvastatin Versus Doubling the Dose of Atorvastatin in Patients With Hypercholesterolemia and Risk Factors (P03708)
This study assesses whether adding ezetimibe 10 mg/d to ongoing treatment with atorvastatin 10 mg/d is more effective than switching the subject to treatment with rosuvastatin 10 mg/d or doubling the dose of atorvastatin to 20…
- Conditions
- Hypercholesterolemia, Atherosclerosis, Coronary Artery Disease
- Trial name
- NCT00651378
- Testing
- Rosuvastatin, Ezetimibe + Atorvastatin, Double Atorvastatin
- Volunteers
- 87 people
- Sponsor
- Organon and Co
Type II Diabetes
Effect of Dapagliflozin on 24-hour Blood Glucose in T2DM Patients Inadequately Controlled With Either Metformin Or Insulin
Effect of Dapagliflozin on 24-hour Blood Glucose in Type 2 Diabetes Patients Inadequately Controlled With Either Metformin Or Insulin
- Trial name
- NCT02429258
- Testing
- Farxiga, Metformin, Insulin
- Where
- 26 sites in United States
- Volunteers
- 226 people
- Sponsor
- AstraZeneca
Non-Small Cell Lung Cancer, Colorectal Cancer
A Study of a Personalized Cancer Vaccine Targeting Shared Neoantigens
The purpose of this study is to evaluate the dose, safety, immunogenicity and early clinical activity of GRT-C903 and GRT-R904, a neoantigen-based therapeutic cancer vaccine, in combination with immune checkpoint blockade, in…
- Conditions
- Non-Small Cell Lung Cancer, Colorectal Cancer, Pancreatic Cancer, Solid Tumor
- Trial name
- NCT03953235
- Testing
- GRT-C903, GRT-R904, nivolumab
- Where
- 12 sites in United States
- Volunteers
- 39 people
- Sponsor
- Gritstone bio, Inc.
Type 2 Diabetes Mellitus
Efficacy and Safety of Efpeglenatide Versus Placebo in Patients With Type 2 Diabetes Mellitus Inadequately Controlled With Basal Insulin Alone or in Combination With Oral Antidiabetic Drug(s)
Primary Objective: To demonstrate the superiority of once weekly injection of efpeglenatide in comparison to placebo in glycated hemoglobin (HbA1c) change in participants with type 2 diabetes mellitus (T2DM) inadequately…
- Trial name
- AMPLITUDE-L (NCT03713684)
- Testing
- Efpeglenatide SAR439977, Background therapy
- Where
- 47 sites in United States, China and 1 more
- Volunteers
- 370 people
- Sponsor
- Sanofi
The first 1,020 results can be paged through. Add a filter or change the sort order to reach the rest.